scholarly journals Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantation

2011 ◽  
Vol 86 (10) ◽  
pp. 873-875 ◽  
Author(s):  
Victor H. Jimenez-Zepeda ◽  
Suzanne Trudel ◽  
Donna E. Reece ◽  
Christine Chen ◽  
Ahmed M. Rabea ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Poems Syndrome ◽  
Engraftment Syndrome ◽  
Undergo Stem Cell Transplantation

scholarly journals COVID-19 during Early Phase of Autologous Stem Cell Transplantation

Medicina ◽  
2021 ◽  
Vol 57 (7) ◽  
pp. 724
Author(s):  
Sławomir Milczarek ◽  
Bartłomiej Baumert ◽  
Anna Sobuś ◽  
Ewa Wilk-Milczarek ◽  
Krzysztof Sommerfeld ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Early Phase ◽  
Hematopoietic Stem ◽  
Prolonged Incubation ◽  
Heavily Pretreated ◽  
Engraftment Syndrome ◽  
Interesting Correlation ◽  
Neutrophil Engraftment

We present one of few cases of COVID-19 occurrence during the early phase of autologous hematopoietic stem cell transplantation. We observed an interesting correlation between the patient’s rapid clinical deterioration and myeloid reconstitution that cannot be assigned to engraftment syndrome. Our report emphasizes the need to investigate whether timely steroid therapy upon neutrophil engraftment in the setting of COVID-19 could limit the extent of lung injury and prevent ARDS. Furthermore, we discuss a significant issue of possible prolonged incubation of the virus in heavily pretreated hematological patients.

POEMS syndrome treated with autologous hematopoietic stem cell transplantation

2019 ◽  
Vol 85 ◽  
pp. S44-S45
Author(s):  
E. Abdullayev ◽  
E. Abdullayev ◽  
H. Baurmann ◽  
C. Eimermacher ◽  
B. Glass
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Poems Syndrome ◽  
Hematopoietic Stem

Should Young Patients with e19a2 Type BCR/ABL Rearrangement Undergo Stem Cell Transplantation?

2003 ◽  
Vol 44 (2) ◽  
pp. 381-382 ◽  
Author(s):  
Fumihiko Nakamura ◽  
Seishi Ogawa ◽  
Koji Izutsu ◽  
Yoichi Imai ◽  
Kazuhiro Maki ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Young Patients ◽  
Undergo Stem Cell Transplantation

scholarly journals Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: A Nationwide Survey in Japan

2018 ◽  
Vol 24 (6) ◽  
pp. 1180-1186 ◽  
Author(s):  
Chika Kawajiri-Manako ◽  
Emiko Sakaida ◽  
Chikako Ohwada ◽  
Toshihiro Miyamoto ◽  
Taichi Azuma ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Nationwide Survey ◽  
Poems Syndrome ◽  
Long Term Outcomes

scholarly journals A patient with POEMS syndrome responding to modified CyBorD chemotherapy as a bridge to autologous stem cell transplantation

2019 ◽  
Vol 5 (3) ◽  
pp. 228-230 ◽  
Author(s):  
Emily C. Milam ◽  
Kathryn J. Martires ◽  
Kristen I. Lo Sicco ◽  
David J. Araten ◽  
Andrew G. Franks
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Poems Syndrome

Syngeneic Donor Hematopoietic Stem Cell Transplantation Is Associated with High Rates of Engraftment Syndrome

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1323-1323
Author(s):  
John Koreth ◽  
Melinda Biernacki ◽  
Julie Aldridge ◽  
Haesook T Kim ◽  
Edwin P Alyea ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Risk ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Competing Risks ◽  
Cumulative Incidence ◽  
Hla Class I ◽  
Hematopoietic Stem ◽  
Engraftment Syndrome

Abstract Abstract 1323 Engraftment syndrome (ES), typically characterized by non-infectious fever, rash and/or non-cardiogenic pulmonary edema, is a complication of autologous and allogeneic hematopoietic stem cell transplantation (HSCT). There is no data on ES after syngeneic HSCT. We retrospectively analyzed syngeneic HSCT outcomes and determined ES incidence, risk factors, and prognostic impact. 32 adult patients with a median age of 46 years (range, 22–60) underwent syngeneic HSCT at our institution between July 1986-April 2009, primarily for hematologic malignancies (31% myeloid, 66 % lymphoid-including 16% plasma cell). Syngeneic donor typing methods varied over the time-period of this report and included: serologic HLA Class I and II typing; confirmatory SSP molecular HLA Class I typing; molecular PCR-RFLP and SSP HLA Class II typing; and STR genotyping using ABI Profile Plus Kit Human Identity markers. Patient characteristics: 15 (47%) were male; 28 (88%) had high-risk disease; 18 (56%) received total-body irradiation (TBI) as a component of myeloablative conditioning; 16 (50%) received donor peripheral blood stem cell infusion; and 14 (41%), 10 (31%) and 9 (28%) had low-, intermediate- and high-risk HCT-comorbidity index score respectively. No graft-versus-host-disease prophylaxis, T-cell depletion, or pre-emptive or prophylactic donor lymphocyte infusion was utilized. The median duration of follow-up was 6.1 years (range, 3.7 months-18.1 years). 5-year progression-free and overall survival (PFS, OS) was 52% and 67% respectively. 5-year overall cumulative incidence of relapse and non-relapse mortality (NRM) was 37.6% and 10.2% respectively. 15 patients (47%) met diagnostic criteria for ES, 10 (67%) of whom received a brief course of systemic steroids with prompt clinical response in all except one patient (who died of respiratory failure). Patient age ≥50 years was a risk factor for developing ES (p=0.05). Median time to engraftment was 12 days in patients with ES vs. 11.5 days in those without ES. 5-year PFS was 47% in patients with ES vs. 56% in those without (p=0.37). 5-year OS was 63% with ES vs. 71% without (p=0.8). 5-year cumulative incidence of relapse was 32% with ES and 44% without (p=0.68). 5-year cumulative incidence of NRM was 21% with ES vs. 0% without (p=0.06). In multivariable Cox-models only myeloid diagnosis (vs. lymphoid) impaired PFS and OS (HR 4.83, 95% CI 1.33–17.53, p=0.02; HR 8.47, 95% CI 1.73–41.58, p<0.01 respectively). In summary, we document a high incidence of ES after syngeneic HSCT. While syngeneic ES did not impact HSCT survival outcomes, the trend of increased NRM with ES is concerning and needs re-evaluation in a larger cohort.Figure:Cumulative Incidence of Relapse and NRM as Competing Risks-by ES cohortFigure:. Cumulative Incidence of Relapse and NRM as Competing Risks-by ES cohort Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document